COR

Cencora is a defensive, secularly-growing pharmaceutical distributor, and the top line shows it: revenue has climbed every year from $214B (FY21) to $321B (FY25), with the latest +9.3% (+$27.4B) driven by both the U.S. and International segments per the MD&A executive summary. Distribution is a penny-margin, high-velocity business by design, so the 3.6% gross / 0.8% operating / 0.5% net margins are structural, not distress — the more important signal is that FY25 gross profit (+15.8%) and operating income (+20.8%) grew well ahead of revenue, hinting at genuine operating leverage. Cash generation is the real strength: $3.88B operating cash flow against just $668M capex funds a growing dividend ($437M) and buybacks while the headline ROE of 103% simply reflects a tiny equity base, not superior returns.

The problem is that this quality is largely in the price and bottom-line growth has stalled. GAAP net income has gone essentially nowhere in four years — $1.54B (FY21) to $1.55B (FY25), up only 3.0% in the latest year — even as revenue grew ~50% cumulatively; the gap between strong operating-income growth and flat net income points to rising interest and below-the-line costs. The balance sheet is thin and more levered: stockholders' equity is just $1.51B against $7.54B of long-term debt, which nearly doubled (+97.9%) this year, and current liabilities ($57.8B) exceed current assets ($52.2B). On the figures provided, the stock trades at 34.1x FY diluted EPS of $7.96 — a premium multiple for a business whose GAAP earnings barely grow.